Atrion (NASDAQ:ATRI – Get Rating) and Minerva Surgical (NASDAQ:UTRS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations for Atrion and Minerva Surgical, as provided by MarketBeat.
Get
Atrion alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Atrion | 0 | 0 | 0 | 0 | N/A |
| Minerva Surgical | 1 | 0 | 1 | 0 | 2.00 |
Minerva Surgical has a consensus target price of $5.00, indicating a potential upside of 1,983.33%. Given Minerva Surgical's higher possible upside, analysts clearly believe Minerva Surgical is more favorable than Atrion.
Earnings & Valuation
This table compares Atrion and Minerva Surgical's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Atrion | $165.01 million | 6.36 | $33.06 million | $19.35 | 30.59 |
| Minerva Surgical | $52.10 million | 0.13 | -$21.46 million | N/A | N/A |
Atrion has higher revenue and earnings than Minerva Surgical.
Risk and Volatility
Atrion has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500.
Institutional & Insider Ownership
64.9% of Atrion shares are held by institutional investors. Comparatively, 65.1% of Minerva Surgical shares are held by institutional investors. 22.7% of Atrion shares are held by insiders. Comparatively, 7.0% of Minerva Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Atrion and Minerva Surgical's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Atrion | 19.24% | 14.16% | 12.82% |
| Minerva Surgical | -34.03% | -51.99% | -17.35% |
Summary
Atrion beats Minerva Surgical on 8 of the 11 factors compared between the two stocks.
About Atrion
(Get Rating)
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
About Minerva Surgical
(Get Rating)
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.
